Lee Hye Jin, Kim Ki Cheon, Lee Woo Jin, Nam Hyo Jung, Ryu Su Jin, Kim Seon Hyeok, Kim Won Jun, Yoon Jae Won, Lee Tae-Hee, Jeong Pan-Young
Department of Efficacy Evaluation, Centralbio Co., Ltd., Incheon, Republic of Korea.
Life Science Research Institute, Novarex Co., Ltd., Cheongju, Chungbuk, Republic of Korea.
Front Nutr. 2025 Jul 10;12:1613413. doi: 10.3389/fnut.2025.1613413. eCollection 2025.
Allergic asthma involves chronic inflammation, airway remodeling, and hyperresponsiveness. Inhaled corticosteroids combined with long-acting β2 agonists are effective; however, some patients experience side effects, highlighting the need for safer natural alternatives suitable for long-term use. (Q) and (SC) are used to treat various diseases, including asthma and inflammation. Q and SC extracts contain bioactive compounds that help modulate airway inflammation. Therefore, combining the two may enhance their immunomodulatory effects. However, the effects of a Q/SC mixture on allergic asthma remain unclear. The aim of this study is to assess the therapeutic effectiveness of a Q/SC mixture in treating asthma.
The therapeutic efficacy of the Q/SC extract was evaluated in an ovalbumin (OVA)-induced allergic airway inflammation model. After euthanasia, we assessed cell counts, cytokine expression in the bronchoalveolar lavage fluid (BALF), blood immunoglobulin (Ig) E levels, inflammatory cell infiltration, mucus production in the lung tissue, and the expression of protein and cytokine.
A high-concentration Q/SC extract significantly reduced total cell and eosinophil counts, cytokine expression in BALF, and serum IgE levels. Furthermore, it reduced the expression of type 2 cytokines (IL-4, IL-5, IL-13) and inducible nitric oxide synthase in lung tissue. The extract also attenuated inflammatory cell infiltration and mucus production while inhibiting the STAT6 signaling pathway.
A high concentration of Q/SC extract effectively alleviates allergic airway inflammation by reducing eosinophilic inflammation, type 2 cytokine secretion, and mucus hyperproduction. This suggests that it could be a potential remedy for managing allergic airway inflammation.
过敏性哮喘涉及慢性炎症、气道重塑和高反应性。吸入性糖皮质激素联合长效β2受体激动剂是有效的;然而,一些患者会出现副作用,这凸显了对适合长期使用的更安全天然替代品的需求。(Q)和(SC)被用于治疗包括哮喘和炎症在内的各种疾病。Q和SC提取物含有有助于调节气道炎症的生物活性化合物。因此,将两者结合可能会增强它们的免疫调节作用。然而,Q/SC混合物对过敏性哮喘的影响仍不清楚。本研究的目的是评估Q/SC混合物治疗哮喘的疗效。
在卵清蛋白(OVA)诱导的过敏性气道炎症模型中评估Q/SC提取物的治疗效果。安乐死后,我们评估了细胞计数、支气管肺泡灌洗液(BALF)中的细胞因子表达、血液免疫球蛋白(Ig)E水平、炎症细胞浸润、肺组织中的黏液产生以及蛋白质和细胞因子的表达。
高浓度的Q/SC提取物显著降低了总细胞和嗜酸性粒细胞计数、BALF中的细胞因子表达以及血清IgE水平。此外,它还降低了肺组织中2型细胞因子(IL-4、IL-5、IL-13)和诱导型一氧化氮合酶的表达。该提取物还减轻了炎症细胞浸润和黏液产生,同时抑制了STAT6信号通路。
高浓度的Q/SC提取物通过减少嗜酸性炎症、2型细胞因子分泌和黏液过度产生,有效减轻了过敏性气道炎症。这表明它可能是治疗过敏性气道炎症的一种潜在药物。